Home Blog of Signal Transduction Autophagy ATM/ATR P2X7 receptor is a key upstream regulator for main signaling pathways involved in neuroblastoma progression

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

P2X7 receptor is a key upstream regulator for main signaling pathways involved in neuroblastoma progression

 

Neuroblastoma (NB) is a neuroendocrine tumor that responsible for 15% of pediatric cancer deaths in childhood. Due to the lack of effective therapeutic strategy for advanced-stage patients, many studies aim at investigation of targets for clinical intervention against NB. Amoroso et al. demonstrated that P2X7 plays a key role in regulating the PI3K/Akt/GSK3β/MYCN and HIF1α/VEGF pathways, two main signaling pathways involved in NB progression. The article was published online in Oncogene.

 

P2X7, a receptor of extracellular ATP, is the best candidate responsible for tumor progression. This study showed P2X7 promotes PI3K/Akt and HIFα activation, GSK3β downregulation, VEGF secretion, and glycogen accumulation in ACN human NB cells. Two different P2X7 antagonists, AZ10606120 and A740003, can significantly suppress ACN-derived tumor progression in nude/nude mice. Furthermore, the blockade of P2X7 strongly reduced the expression level of MYCN, the best-known oncogene in NB. These findings are consistent with the overexpression of P2X7 in advanced-stage NB patients with poor prognosis. In summary, this study suggests that P2X7 receptor is an upstream mediator of PI3K/Akt/GSK3β/MYCN and HIF1α/VEGF pathways for regulating NB progression, metabolic activity and angiogenesis, indicating it may become a therapeutic target for NB treatment in the future.

 

Reference:
Oncogene. 2015 Jan 26. doi: 10.1038/onc.2014.444.

Related Products

Cat.No. Product Name Information
S1105 LY294002 LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
S1009 Dactolisib (BEZ235) Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

Related Targets

ATM/ATR mTOR Autophagy PI3K